Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Conference name: 2nd International conference on pathology

Short name: Pathology 2019

Venue : Paris,France | July 5-6,2019

URL: https://bit.ly/2GS09CI

 A total of 159 patients with biological-naïve AS, with active disease (Bath Ankylosing Spondylitis Disease Activity Index score of ≥4), were randomised (1:1:1:1) to risankizumab (18 mg single dose, 90 mg or 180 mg at day 1 and weeks 8, 16 and 24) or placebo over a 24-week blinded period. The primary outcome was a 40% improvement in Assessment in Spondylo Arthritis International Society (ASAS40) at week 12. Safety was assessed in patients who received at least one dose of study drug.

Author:Dr.James Cheng

Treatment with risankizumab did not meet the study primary endpoint and showed no evidence of clinically meaningful improvements compared with placebo in patients with active AS, suggesting that IL-23 may not be a relevant driver of disease pathogenesis and symptoms in AS.

To know more about Pathology and its Applications do attend International Conference on Pathology 2019 http://pathology.alliedacademies.com/

Contact
KRISTIE NOVA
Program Director | PATHOLOGY 2019
Phone: (44) 20 3769 1755
Email: pathology(at)alliedannualsummit(dot)com